GYNECOLOGICAL CANCER DRUGS MARKET ANALYSIS

Gynecological Cancer Drugs Market, By Therapeutic Modality (Chemotherapy, Targeted Therapy, and Hormonal Therapy), By Indication (Uterine Cancer, Ovarian Cancer, Vaginal & Vulvar Cancer, and Cervical Cancer), and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI1744
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Gynecological Cancer Drugs Market - Regional Insights

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounted for the largest share in the gynecological cancer drugs market, followed by Europe market in 2016. This is attributed to increasing prevalence of cervical cancer in the U.S. According to Center for Disease Control and Prevention in 2014, 12,578 women in the U.S. ware diagnosed with cervical cancer and 4,115 women died from cervical cancer. Therefore, this is expected to lead to increasing demand for gynecological cancer drugs in North America.

Furthermore, Asia Pacific is estimated to grow at faster rate due to large population pool and government initiatives to create awareness regarding gynecological cancer. For instance, the Indian government published an operational framework for the country’s first national screening programmne, in 2016, where there will be mandatory screening for oral, breast, and cervical cancer in people over the age of 30 in 100 districts of India.